Gents. Just for some perspective on possible takeovers here is a...

Gents. Just for some perspective on possible takeovers here is a list of the top 10 M&A deals for 2021. Below is a very high level summary and the link to the site is below. My point is that none of these have gone above 118% premium over previous days SP or stated average

CSL and Vifor Pharma Deal value: $11.7 billion Premium: 40% on the 60-day average price of Vifor's stock Date announced: Dec. 14, 2021
Merck & Co and Acceleron Deal value: $11.5 billion Premium: 34% to the stock's Aug. 31 closing price Date announced: Sept. 30, 2021
Jazz Pharmaceuticals and GW Pharmaceuticals Deal value: $7.2 billion Premium: Around 50% over GW's prior-day closing price Date announced: Feb. 3, 2021
Pfizer and Arena Pharmaceuticals Deal value: $6.7 billion Premium: 100% over Arena's prior-day stock price Date announced: Dec. 13, 2021
Novo Nordisk and Dicerna Pharmaceuticals Deal value: $3.3 billion Premium: 80% over the prior-day closing price Date announced: Nov. 18, 2021
Sanofi and Translate Bio Deal value: $3.2 billion Premium: 56% over average price over previous 60 days Date announced: Aug. 3, 2021
Horizon Therapeutics and Viela Bio Deal value: $3.05 billion Premium: 53% over prior-day closing price Date announced: Feb. 1, 2021
Pfizer and Trillium Therapeutics Deal value: $2.26 billion Premium: 118% over the 60-day weighted average price of Trillium’s stock Date announced: Aug. 23, 2021
Perrigo and HRA Pharma Deal value: $2.1 billion Premium: Not applicable Date announced: Sept. 8, 2021
Amgen and Five Prime Therapeutics Deal value: $1.9 billion Premium: 78% over its previous day close Date announced: March 4, 2021
Sanofi and Kadmon Holdings Deal value: $1.9 billion Premium: 79% over the previous-day closing price Date announced: Sept. 8, 2021

Basic average calculation 68%. Based on current SP approx $11.20 or approx $1.5B mcap.

https://www.fiercepharma.com/special-report/top-10-biopharma-m-a-deals-2021